Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

9.095 +0.345 (+3.94%)
Streaming Delayed Price Updated: 1:32 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
News headline image
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? ↗
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010. 
Via Stocktwits
News headline image
3 Cash-Heavy Stocks That Fall Short
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks We Steer Clear Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also... 
Via StockStory
Topics Stocks
News headline image
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗
The business may not be as strong as its performance this year suggests. 
Via The Motley Fool
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Novavax's Earnings ↗
 
Via Benzinga
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Are Novavax (NVAX) Shares Soaring Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗
The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas. 
Via Stocktwits
News headline image
2 Growth Stocks with Explosive Upside and 1 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
Via Chartmill
Topics Government
News headline image
CORRECTED: Why Is Novavax Stock Soaring? ↗
Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States. 
Via Benzinga
Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks
Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NVAX) Stock Trades Up, Here Is Why
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics in Singapore. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novavax (NASDAQ:NVAX) Surprises With Q3 CY2025 Sales
Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s... 
Via StockStory
Topics Artificial Intelligence
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge... 
Via MarketMinute
Topics Intellectual Property
News headline image
Why I Wouldn't Touch Novavax With a 10-Foot Pole ↗
This stock could be a wealth destroyer in the next five years. 
Via The Motley Fool
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. 
Via Investor's Business Daily
Topics Death
News headline image
Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale ↗
Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial results has become “striking.” 
Via Stocktwits
News headline image
Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance ↗
The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program. 
Via Stocktwits
News headline image
AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
News headline image
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
News headline image
Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity ↗
Shah Capital currently owns 11.8 million shares or 7.2% of Novavax. 
Via Stocktwits
News headline image
ConnectM Exits Nasdaq for OTCQB Venture Market: A Deep Dive into Delisting, Challenges, and a Path Forward
ConnectM Technology Solutions (OTCQB: CMMU), a company specializing in green energy technology, has officially transitioned its trading to the OTCQB Venture Market, effective October 2, 2025, following... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
India's Tech Ascent: A 'Mission Mode' for Global Leadership in Semiconductors, Quantum, AI, and Biomanufacturing
India is embarking on an ambitious "mission mode" strategy, signaling a profound shift in its national policy to establish itself as a global leader in critical and emerging technologies. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Novavax Amends Deal With Sanofi, Broadens Partnership ↗
The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate. 
Via Stocktwits
News headline image
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' ↗
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.